TY - JOUR
T1 - Nonproteinuric versus proteinuricphenotypesindiabetic kidney disease
T2 - A propensity score–matched analysis of a nationwide, biopsy-based cohort study
AU - Yamanouchi, Masayuki
AU - Furuichi, Kengo
AU - Hoshino, Junichi
AU - Toyama, Tadashi
AU - Hara, Akinori
AU - Shimizu, Miho
AU - Kinowaki, Keiichi
AU - Fujii, Takeshi
AU - Ohashi, Kenichi
AU - Yuzawa, Yukio
AU - Kitamura, Hiroshi
AU - Suzuki, Yoshiki
AU - Sato, Hiroshi
AU - Uesugi, Noriko
AU - Hisano, Satoshi
AU - Ueda, Yoshihiko
AU - Nishi, Shinichi
AU - Yokoyama, Hitoshi
AU - Nishino, Tomoya
AU - Samejima, Kenichi
AU - Kohagura, Kentaro
AU - Shibagaki, Yugo
AU - Mise, Koki
AU - Makino, Hirofumi
AU - Matsuo, Seiichi
AU - Ubara, Yoshifumi
AU - Wada, Takashi
N1 - Publisher Copyright:
© 2019 by the American Diabetes Association.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - OBJECTIVE Clinicopathological characteristics, renal prognosis, and mortality in patients with type 2 diabetes and reduced renal function without overt proteinuria are scarce. RESEARCH DESIGN AND METHODS We retrospectively assessed 526 patients with type 2 diabetes and reduced renal function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), who underwent clinical renal biopsy and had follow-up data, from Japan’s nationwide multicenter renal biopsy registry. For comparative analyses, we derived one-to-two cohorts of those without proteinuria versus those with proteinuria using propensity score–matching methods addressing the imbalances of age, sex, diabetes duration, and baseline eGFR. The primary end point was progression of chronic kidney disease (CKD) defined as new-onset end-stage renal disease, decrease of eGFR by ‡50%, or doubling of serum creatinine. The secondary end point was all-cause mortality. RESULTS Eighty-two patients with nonproteinuria (urine albumin-to-creatinine ratio [UACR] <300 mg/g) had lower systolic blood pressure and less severe pathological lesions compared with 164 propensity score–matched patients with proteinuria (UACR ‡300 mg/g). After a median follow-up of 1.9 years (interquartile range 0.9–5.0 years) from the date of renal biopsy, the 5-year CKD progression-free survival was 86.6% (95% CI 72.5–93.8) for the nonproteinuric group and 30.3% (95% CI 22.4–38.6) for the proteinuric group (log-rank test P < 0.001). The lower renal risk was consistent across all subgroup analyses. The all-cause mortality was also lower in the nonproteinuric group (log-rank test P 5 0.005). CONCLUSIONS Patients with nonproteinuric diabetic kidney disease had better-controlled blood pressure and fewer typical morphological changes and were at lower risk of CKD progression and all-cause mortality.
AB - OBJECTIVE Clinicopathological characteristics, renal prognosis, and mortality in patients with type 2 diabetes and reduced renal function without overt proteinuria are scarce. RESEARCH DESIGN AND METHODS We retrospectively assessed 526 patients with type 2 diabetes and reduced renal function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), who underwent clinical renal biopsy and had follow-up data, from Japan’s nationwide multicenter renal biopsy registry. For comparative analyses, we derived one-to-two cohorts of those without proteinuria versus those with proteinuria using propensity score–matching methods addressing the imbalances of age, sex, diabetes duration, and baseline eGFR. The primary end point was progression of chronic kidney disease (CKD) defined as new-onset end-stage renal disease, decrease of eGFR by ‡50%, or doubling of serum creatinine. The secondary end point was all-cause mortality. RESULTS Eighty-two patients with nonproteinuria (urine albumin-to-creatinine ratio [UACR] <300 mg/g) had lower systolic blood pressure and less severe pathological lesions compared with 164 propensity score–matched patients with proteinuria (UACR ‡300 mg/g). After a median follow-up of 1.9 years (interquartile range 0.9–5.0 years) from the date of renal biopsy, the 5-year CKD progression-free survival was 86.6% (95% CI 72.5–93.8) for the nonproteinuric group and 30.3% (95% CI 22.4–38.6) for the proteinuric group (log-rank test P < 0.001). The lower renal risk was consistent across all subgroup analyses. The all-cause mortality was also lower in the nonproteinuric group (log-rank test P 5 0.005). CONCLUSIONS Patients with nonproteinuric diabetic kidney disease had better-controlled blood pressure and fewer typical morphological changes and were at lower risk of CKD progression and all-cause mortality.
UR - http://www.scopus.com/inward/record.url?scp=85065098219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065098219&partnerID=8YFLogxK
U2 - 10.2337/dc18-1320
DO - 10.2337/dc18-1320
M3 - Article
C2 - 30833372
AN - SCOPUS:85065098219
SN - 0149-5992
VL - 42
SP - 891
EP - 902
JO - Diabetes care
JF - Diabetes care
IS - 5
ER -